Skip to main content

TEVA Teva Pharmaceutical Industries Limited

Healthcare

41.10

Close 10/9

Open
40.22
High
42.02
Low
40.12
Prev close
39.25
Volume
14.4M
52W 18.83 42.02
Loading candles…

Is Teva Pharmaceutical Industries Limited a buy? Fundamentals and valuation first

As of 2026-10-09

Quality: Good, Momentum: Strong, Risk / liquidity: Good.

Quality Good All 3 indicators are Good.
ROE, TTM (%) 9.1 61th percentile Good
Operating margin, TTM (%) 11.45 59th percentile Good
FCF margin, TTM (%) 7.79 57th percentile Good
Growth Neutral Revenue growth, TTM YoY is Average.
Revenue growth, TTM YoY (%) 4.13 46th percentile Average
Momentum Strong All 2 indicators are Top.
60-day return (%) 27.56 92th percentile Top
240-day return (%) 116.89 96th percentile Top
Risk / liquidity Good 20-day dollar volume is Top; 60-day annualized volatility is Good.
20-day dollar volume 229,312,361 93th percentile Top
60-day annualized volatility (%) 35.27 40th percentile Good

Teva Pharmaceutical Industries Limited (TEVA) today

2 quant signals active · As of 2026-10-09

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

Teva Pharmaceutical Industries Limited (TEVA) peers and tracking

Watchlist

This page refreshes daily after the close. Add Teva Pharmaceutical Industries Limited to your watchlist to track signal changes on your next visit.

Teva Pharmaceutical Industries Limited (TEVA) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

52-week adjusted-price high

Active

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

11 historical occurrences (since 2018-08-20)
Average forward return after 52-week adjusted-price high。20-day: Win 54.5%, Sample 11, Median +1.01%, Excess -1.02%, Beat mkt rate 54.5%；60-day: Win 50%, Sample 10, Median -0.45%, Excess +1.25%, Beat mkt rate 40%；120-day: Win 44.4%, Sample 9, Median -2.9%, Excess -1.31%, Beat mkt rate 44.4%

120 days after: historical avg +5.51%

20-day +0.18%
60-day +1.6%
120-day +5.51%
20-day
60-day
120-day
Win
54.5%
50%
44.4%
Sample
11
10
9
Median
+1.01%
-0.45%
-2.9%
Excess
-1.02%
+1.25%
-1.31%
Beat mkt rate
54.5%
40%
44.4%

Over 9 occurrences, 120-day forward avg gained 5.51%, lagged the market by 1.31 pts; win rate 44.4%.

Top-quintile 6-month momentum

Active · now 82.58%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

19 historical occurrences (since 2018-04-20)
Average forward return after Top-quintile 6-month momentum。20-day: Win 66.7%, Sample 18, Median +4.29%, Excess +4.92%, Beat mkt rate 61.1%；60-day: Win 61.1%, Sample 18, Median +5.33%, Excess +8.59%, Beat mkt rate 66.7%；120-day: Win 58.8%, Sample 17, Median +11.65%, Excess +4.71%, Beat mkt rate 52.9%

120 days after: historical avg +9.36%

20-day +7.48%
60-day +8.68%
120-day +9.36%
20-day
60-day
120-day
Win
66.7%
61.1%
58.8%
Sample
18
18
17
Median
+4.29%
+5.33%
+11.65%
Excess
+4.92%
+8.59%
+4.71%
Beat mkt rate
61.1%
66.7%
52.9%

Over 17 occurrences, 120-day forward avg gained 9.36%, beat the market by 4.71 pts; win rate 58.8%.

More history: Market-wide momentum baseline, Signals not active now

Market-wide momentum baseline

Across 98,394 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.23%, a 57.8% positive-return rate, and +2.88 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

Continue researching Teva Pharmaceutical Industries Limited with the evidence above.

Continue in Studio ↗

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.
  • This is an American depositary receipt (ADR). The data does not say how many ordinary shares each ADR represents, so per-share and market-value metrics (P/E, price/book, free-cash-flow yield, EPS growth and earnings surprises) are not computed.
  • ADRs listed on NYSE or NASDAQ are covered as a separate group selected by dollar volume, in addition to the common-stock universe; the 6-month momentum signal ranks each ADR against the liquid US common stocks.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.